Impact of an educational intervention on steroid prescribing and dosing effect on patient outcomes in COPD exacerbations
The increasing number of patients affected by chronic obstructive pulmonary disease (COPD) and associated exacerbations has led to both rising hospital admissions and significant economic impact. Evidence-based guidelines have been formulated for COPD management recommending the use of low dose, oral corticosteroid therapy in the treatment of exacerbations. However, fewer than 50% of physicians’ prescribing practices appropriately reflect the published clinical guidelines on the use of systemic corticosteroids in these patients.
Objective. The purpose of this study was to evaluate the impact of a pharmacist-led educational intervention on prescribing practices and patient outcomes when using systemic corticosteroids in patients with COPD exacerbations.
Methods. This retrospective case-control study included patients admitted to an inpatient family medicine service with a COPD exacerbation who received systemic corticosteroids. Two pharmacist-led educational interventions were delivered to prescribers to review current guidelines for managing COPD exacerbations with systemic corticosteroids. Patients were retrospectively identified over a three month span prior to and following the educational intervention. Data was collected via chart review to evaluate prescribing practices prior to and following the educational sessions. In addition, data was collected to evaluate the effects of an educational intervention on length of stay, adverse events, and cost of treatment.
Results. A total of 23 pre-intervention patients and 18 post-intervention patients met inclusion criteria. After pharmacist-led interventions, guidelines were not more likely to be adhered to by prescribers when compared to guideline adherence in the pre-intervention patients. Because no statistically significant change in guideline adherence was observed, there was no impact on secondary outcomes.
Conclusion. Pharmacist-led didactic educational interventions and guideline dissemination do not improve guideline adherence and prescribing practices with respect to systemic corticosteroids in COPD exacerbations.
2. Strassels SA, Smith DH, Sullivan SD, Mahajan PS. The costs of treating COPD in the United States. Chest. 2001;119:344-352.
3. Davies L, Angus RM, Calverley A. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomized controlled trial. Lancet. 1999;354:456-460.
4. Niewoehner DE, Erbland ML, Deupree RH, Collins D, Gross NJ, Light RW, Anderson P, Morgan N. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. N Engl J Med. 1999;340:1941-1947.
5. Tashkin DP. Oral vs IV corticosteroids for in-hospital treatment of COPD exacerbations. Chest. 2007;132:1728-1729.
6. de Jong YP, Uil SM, Grotjohan HP, Postma DS, Kerstjens HAM, van den Berg JWK. Oral or IV prednisolone in the treatment of COPD exacerbations: A randomized, controlled, double-blind study. Chest. 2007;132:1741-1747.
7. Global stategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (GOLD). Executive Summary. Updated 2007. www.goldcopd.com (Accessed 2008 December 18).
8. Siafakas NM, Vermeire P, Pride NB, Paoletti P, Gibson J, Howard P, Yernault JC, Decramer M, Higenbottam T, Postma DS, Rees J. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). ERS- Consensus statement. Eur Respir J. 1995;8:1398-1420.
9. Celli BR, MacNee W, Agusti A, Anzueto A, Berg B, Buist AS, Calverley PMA, Chavannes N, Dillard T, Fahy B, Fein A, Heffner J, Lareau S, Meek P, Martinez F, McNicholas W, Muris J, Austegard E, Pauwels R, Rennard S, Rossi A, Siafakas N, Tiep B, Vestbo J, Wouters E, ZuWallack R. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23:932-946.
10. Davis DA, Taylor-Vaisey A. Translating guidelines into practice: A systematic review of theoretic concepts, practical experience and research evidence in the adoption of clinical practice guidelines. Can Med Assoc J. 1997;157:408-416.
11. Grol R. Successes and failures in the implementation of evidence-based guidelines for clinical practice. Med Care. 2001;39(8):II-46-II-54.
12. Rodriguez-Roisin R. COPD exacerbations-5: Management. Thorax. 2006;61:535-544.
13. Self TH, Smith SL, Boswell RL, Miller WA. Medical education provided by a clinical pharmacist: Impact on the use and cost of corticosteroid therapy in chronic obstructive pulmonary disease. Drug Intell Clin Pharm. 1982;16:443-447.
14. Bista D, Saha A, Mishra P, Palaian S, Shankar PR. Impact of an educational intervention on the pattern and incidence of potential drug-drug interactions in Nepal. Pharm Pract (Internet). 2009;7(4):242-247.
15. Davis DA, Thomson MA, Oxman AD, Haynes RB. Changing Physician Performance: A Systematic Review of the Effect of Medical Education Strategies. JAMA. 1995;274(9):700-705.
16. Grindrod KA, Patel P, Martin JE. What Interventions Should Pharmacists Employ to Impact Health Practitioners’ Prescribing Practices? Ann Pharmacother. 2006;40:546-57.
17. Ostini R, Hegney D, Jackson C, Williamson M, Mackson JM, Gurman K, Hall W, Tett SE. Systematic Review of Interventions to Improve Prescribing. Ann Pharmacother. 2009;43:502-13.
18. Sketris IS, Langille Ingram EM, Lummis HL. Strategic Opportunities for Optimal Prescribing and Medication Management. Can J Clin Pharmacol. 2009;16(1):e103-e125.
The authors hereby transfer, assign, or otherwise convey to Pharmacy Practice: (1) the right to grant permission to republish or reprint the stated material, in whole or in part, without a fee; (2) the right to print pr epublish copies for free distribution or sale; and (3) the right to republish the stated material in any format (electronic or printed). In addition, the undersigned affirms that the article described above has not previously been published, in whole or part, is not subject to copyright or other rights except by the author(s), and has not been submitted for publication elsewhere, except as communicated in writing to Pharmacy Practice with this document.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC-BY-NC-ND) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.